Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Buys 1,093 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 1,093 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was purchased at an average price of $23.86 per share, with a total value of $26,078.98. Following the transaction, the insider owned 651,114 shares of the company’s stock, valued at approximately $15,535,580.04. This represents a 0.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The shares were purchased at an average cost of $23.57 per share, with a total value of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The stock was acquired at an average cost of $21.94 per share, for a total transaction of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The shares were acquired at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The shares were acquired at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Price Performance

Shares of NASDAQ SRZN opened at $24.48 on Friday. The firm’s 50-day moving average is $21.59 and its two-hundred day moving average is $15.75. The company has a market capitalization of $209.79 million, a PE ratio of -1.10 and a beta of 0.58. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $25.84.

Institutional Trading of Surrozen

A number of institutional investors and hedge funds have recently made changes to their positions in SRZN. China Universal Asset Management Co. Ltd. raised its position in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after buying an additional 500 shares during the period. Citadel Advisors LLC increased its stake in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Surrozen in the 4th quarter worth about $247,000. Geode Capital Management LLC lifted its stake in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Finally, Ieq Capital LLC purchased a new stake in shares of Surrozen during the 4th quarter worth about $304,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.